Price Alert

Zymeworks Inc. (ZYME)

NASDAQ: ZYME · Real-Time Price · USD

14.28

-0.02 (-0.14%)

At close: Aug 15, 2025, 10:19 AM

-0.14% (1D)

Bid	14.16
Market Cap	1.07B
Revenue (ttm)	93.38M
Net Income (ttm)	-113.68M
EPS (ttm)	-0.98
PE Ratio (ttm)	-14.57
Forward PE	-11.13
Analyst	Buy

Ask	14.44
Volume	55,213
Avg. Volume (20D)	462,874
Open	14.05
Previous Close	14.30
Day's Range	14.05 - 14.51
52-Week Range	9.03 - 17.70
Beta	1.26

About ZYME

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ZYME

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ZYME stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Zymeworks has released their quartely earnings on Aug 7, 2025:

Revenue of $48.73M exceeds estimates by $32.95M, with 153.21% YoY growth.

EPS of 0.03 exceeds estimates by 0.51, with 106.12% YoY growth.

Next Earnings Release

Zymeworks Inc. is scheduled to release its earnings on Oct 30, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

-7.97%

Zymeworks shares are trading lower after the compa... Unlock content with Pro Subscription

8 months ago

+9.46%

Zymeworks shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a price target of $18.

News

2 days ago · zacks.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a t...

6 days ago · seekingalpha.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.

1 week ago · zacks.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks Inc. (ZYME) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.52 per share. This compares to a loss of $0.26 per share a year ago.

3 weeks ago · zacks.com

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?

Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r...

1 month ago · zacks.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Ph...

2 months ago · zacks.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

The consensus price target hints at a 76.7% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...